Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab.
Adult
Antibodies, Monoclonal, Humanized
/ administration & dosage
Cohort Studies
Colitis, Ulcerative
/ drug therapy
Crohn Disease
/ drug therapy
Drug Therapy, Combination
Female
Follow-Up Studies
Gastrointestinal Agents
/ administration & dosage
Humans
Immunosuppressive Agents
/ administration & dosage
Male
Middle Aged
Prospective Studies
Registries
Treatment Outcome
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
05
08
2019
accepted:
15
10
2019
pubmed:
5
11
2019
medline:
17
2
2021
entrez:
3
11
2019
Statut:
ppublish
Résumé
Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We prospectively enrolled 310 patients with IBD (191 with Crohn's disease (CD) and 119 patients with ulcerative colitis (UC)) with a follow-up period of 104 weeks (interquartile range: 103-104) in a nationwide registry. The corticosteroid-free clinical remission rate (Harvey Bradshaw Index ≤ 4, Short Clinical Colitis Activity index ≤ 2) at weeks 52 and 104 were 28% and 19% for CD and 27% and 28% for UC, respectively. Fifty-nine percent maintained corticosteroid-free clinical remission between weeks 52 and 104. Vedolizumab with concomitant immunosuppression showed comparable effectiveness outcomes compared with vedolizumab monotherapy (week 104: 21% vs. 23%; P = 0.77), whereas 8 of 13 severe infections occurred in patients treated with concomitant immunosuppression. To conclude, the clinical effect was 19% for CD and 28% for UC after 2 years of follow-up regardless of concomitant immunosuppression.
Identifiants
pubmed: 31677154
doi: 10.1002/cpt.1712
pmc: PMC7232860
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Gastrointestinal Agents
0
Immunosuppressive Agents
0
vedolizumab
9RV78Q2002
Types de publication
Comparative Study
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1189-1199Informations de copyright
© 2019 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Am J Gastroenterol. 2018 Sep;113(9):1345
pubmed: 29946178
J Crohns Colitis. 2020 Jan 1;14(1):33-45
pubmed: 31219157
Clin Gastroenterol Hepatol. 2016 Nov;14(11):1593-1601.e2
pubmed: 26917043
Aliment Pharmacol Ther. 2011 May;33(9):987-95
pubmed: 21366636
N Engl J Med. 2013 Aug 22;369(8):711-21
pubmed: 23964933
Clin Gastroenterol Hepatol. 2019 Apr;17(5):838-846.e2
pubmed: 29935327
Aliment Pharmacol Ther. 2019 Jul;50(1):40-53
pubmed: 31165509
J Crohns Colitis. 2017 Apr 1;11(4):412-424
pubmed: 27683798
Clin Gastroenterol Hepatol. 2012 Sep;10(9):1002-7; quiz e78
pubmed: 22343692
Aliment Pharmacol Ther. 2017 Aug;46(3):310-321
pubmed: 28593685
Dermatology. 2010;221 Suppl 1:43-7
pubmed: 20733314
Aliment Pharmacol Ther. 2018 Oct;48(8):839-851
pubmed: 30281832
Am J Gastroenterol. 2016 Aug;111(8):1147-55
pubmed: 27296941
Dig Dis Sci. 2017 Jun;62(6):1590-1596
pubmed: 28357697
Clin Gastroenterol Hepatol. 2017 Nov;15(11):1750-1757.e3
pubmed: 27890854
N Engl J Med. 2013 Aug 22;369(8):699-710
pubmed: 23964932
J Gastroenterol. 2018 Sep;53(9):1048-1064
pubmed: 29869016
J Crohns Colitis. 2017 Apr 1;11(4):400-411
pubmed: 27683800
Aliment Pharmacol Ther. 2016 Dec;44(11-12):1199-1212
pubmed: 27714831
Clin Gastroenterol Hepatol. 2009 Oct;7(10):1081-8
pubmed: 19577010
Clin Gastroenterol Hepatol. 2018 May;16(5):697-705.e7
pubmed: 29223444
Scand J Gastroenterol. 2017 Jun - Jul;52(6-7):722-729
pubmed: 28362144
Aliment Pharmacol Ther. 2018 Feb;47(4):485-493
pubmed: 29250803